JP2008534613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008534613A5 JP2008534613A5 JP2008504447A JP2008504447A JP2008534613A5 JP 2008534613 A5 JP2008534613 A5 JP 2008534613A5 JP 2008504447 A JP2008504447 A JP 2008504447A JP 2008504447 A JP2008504447 A JP 2008504447A JP 2008534613 A5 JP2008534613 A5 JP 2008534613A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- alkyl
- pharmaceutical composition
- opioid receptor
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 362
- -1 hydroxy, aminocarbonyl Chemical group 0.000 claims description 170
- 239000003814 drug Substances 0.000 claims description 75
- 102000003840 Opioid Receptors Human genes 0.000 claims description 62
- 108090000137 Opioid Receptors Proteins 0.000 claims description 62
- 230000001225 therapeutic Effects 0.000 claims description 37
- 239000002253 acid Substances 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 30
- 230000003364 opioid Effects 0.000 claims description 28
- 108090001120 delta Opioid Receptors Proteins 0.000 claims description 27
- 102000037229 δ-opioid receptors Human genes 0.000 claims description 27
- 239000000556 agonist Substances 0.000 claims description 18
- 230000000202 analgesic Effects 0.000 claims description 14
- 229940079593 drugs Drugs 0.000 claims description 14
- 206010021639 Incontinence Diseases 0.000 claims description 13
- 229940005483 OPIOID ANALGESICS Drugs 0.000 claims description 13
- 230000000051 modifying Effects 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims 147
- 239000008194 pharmaceutical composition Substances 0.000 claims 94
- 239000011780 sodium chloride Substances 0.000 claims 80
- 150000003839 salts Chemical class 0.000 claims 71
- 208000004296 Neuralgia Diseases 0.000 claims 48
- 125000001072 heteroaryl group Chemical group 0.000 claims 37
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 36
- 150000001204 N-oxides Chemical class 0.000 claims 34
- 239000000651 prodrug Substances 0.000 claims 34
- 229940002612 prodrugs Drugs 0.000 claims 34
- 239000012453 solvate Substances 0.000 claims 34
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 31
- 125000003118 aryl group Chemical group 0.000 claims 27
- 125000005418 aryl aryl group Chemical group 0.000 claims 25
- 210000003169 Central Nervous System Anatomy 0.000 claims 24
- OROGSEYTTFOCAN-DNJOTXNNSA-N Codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 24
- 230000001773 anti-convulsant Effects 0.000 claims 24
- 230000001430 anti-depressive Effects 0.000 claims 24
- 239000001961 anticonvulsive agent Substances 0.000 claims 24
- 239000000935 antidepressant agent Substances 0.000 claims 24
- 125000005843 halogen group Chemical group 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 24
- USSIQXCVUWKGNF-UHFFFAOYSA-N Methadone Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 21
- 229960001797 methadone Drugs 0.000 claims 21
- 239000000126 substance Substances 0.000 claims 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 17
- 125000003545 alkoxy group Chemical group 0.000 claims 15
- 125000004432 carbon atoms Chemical group C* 0.000 claims 15
- ANQHWGYYOWWJRU-UHFFFAOYSA-N 2,2-dimethylpropanethial Chemical compound CC(C)(C)C=S ANQHWGYYOWWJRU-UHFFFAOYSA-N 0.000 claims 12
- QIRAYNIFEOXSPW-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-ol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 claims 12
- 229960001391 Alfentanil Drugs 0.000 claims 12
- RDJGWRFTDZZXSM-RNWLQCGYSA-N Benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 claims 12
- 210000001218 Blood-Brain Barrier Anatomy 0.000 claims 12
- 229960001113 Butorphanol Drugs 0.000 claims 12
- IFKLAQQSCNILHL-QHAWAJNXSA-N Butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 12
- YQYVFVRQLZMJKJ-UHFFFAOYSA-N Cyclazocine Chemical compound CC1C2CC3=CC=C(O)C=C3C1(C)CCN2CC1CC1 YQYVFVRQLZMJKJ-UHFFFAOYSA-N 0.000 claims 12
- 229950002213 Cyclazocine Drugs 0.000 claims 12
- 229960002500 DIPIPANONE Drugs 0.000 claims 12
- LNNWVNGFPYWNQE-GMIGKAJZSA-N Desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 claims 12
- XLMALTXPSGQGBX-GCJKJVERSA-N Dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 12
- RBOXVHNMENFORY-DNJOTXNNSA-N Dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 12
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims 12
- RHUWRJWFHUKVED-UHFFFAOYSA-N Dimenoxadol Chemical compound C=1C=CC=CC=1C(C(=O)OCCN(C)C)(OCC)C1=CC=CC=C1 RHUWRJWFHUKVED-UHFFFAOYSA-N 0.000 claims 12
- SVDHSZFEQYXRDC-UHFFFAOYSA-N Dipipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCCCC1 SVDHSZFEQYXRDC-UHFFFAOYSA-N 0.000 claims 12
- ZOWQTJXNFTWSCS-IAQYHMDHSA-N Eptazocine Chemical compound C1N(C)CC[C@@]2(C)C3=CC(O)=CC=C3C[C@@H]1C2 ZOWQTJXNFTWSCS-IAQYHMDHSA-N 0.000 claims 12
- 229960002428 Fentanyl Drugs 0.000 claims 12
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 12
- 229940120060 Heroin Drugs 0.000 claims 12
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 12
- WVLOADHCBXTIJK-YNHQPCIGSA-N Hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 12
- IFKPLJWIEQBPGG-UHFFFAOYSA-N Isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 claims 12
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 claims 12
- RCYBMSQOSGJZLO-BGWNEDDSSA-N Levophenacylmorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CC(=O)C1=CC=CC=C1 RCYBMSQOSGJZLO-BGWNEDDSSA-N 0.000 claims 12
- 229950007939 Levophenacylmorphan Drugs 0.000 claims 12
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 12
- 229960003406 Levorphanol Drugs 0.000 claims 12
- 229950010274 Lofentanil Drugs 0.000 claims 12
- IMYHGORQCPYVBZ-NLFFAJNJSA-N Lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 claims 12
- RDOIQAHITMMDAJ-UHFFFAOYSA-N Loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 claims 12
- 229960001571 Loperamide Drugs 0.000 claims 12
- 229950009131 METAZOCINE Drugs 0.000 claims 12
- 229940041655 Meperidine Drugs 0.000 claims 12
- YGSVZRIZCHZUHB-COLVAYQJSA-N Metazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)CCN(C)[C@@]1([H])[C@@H]2C YGSVZRIZCHZUHB-COLVAYQJSA-N 0.000 claims 12
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 12
- NETZHAKZCGBWSS-CEDHKZHLSA-N Nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims 12
- 229960000805 Nalbuphine Drugs 0.000 claims 12
- DEXMFYZAHXMZNM-UHFFFAOYSA-N Narceine Chemical compound OC(=O)C1=C(OC)C(OC)=CC=C1C(=O)CC1=C(CCN(C)C)C=C(OCO2)C2=C1OC DEXMFYZAHXMZNM-UHFFFAOYSA-N 0.000 claims 12
- HNDXBGYRMHRUFN-CIVUWBIHSA-N Nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 claims 12
- 229950011519 Norlevorphanol Drugs 0.000 claims 12
- WCJFBSYALHQBSK-UHFFFAOYSA-N Normethadone Chemical compound C=1C=CC=CC=1C(CCN(C)C)(C(=O)CC)C1=CC=CC=C1 WCJFBSYALHQBSK-UHFFFAOYSA-N 0.000 claims 12
- ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical compound C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 claims 12
- 229950006134 Normorphine Drugs 0.000 claims 12
- 239000008896 Opium Substances 0.000 claims 12
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycontin Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 12
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 12
- XADCESSVHJOZHK-UHFFFAOYSA-N Petidina Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 12
- LOXCOAXRHYDLOW-UHFFFAOYSA-N Phenadoxone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCOCC1 LOXCOAXRHYDLOW-UHFFFAOYSA-N 0.000 claims 12
- 229950004540 Phenadoxone Drugs 0.000 claims 12
- 229960004315 Phenoperidine Drugs 0.000 claims 12
- XJKQCILVUHXVIQ-UHFFFAOYSA-N Properidine Chemical compound C=1C=CC=CC=1C1(C(=O)OC(C)C)CCN(C)CC1 XJKQCILVUHXVIQ-UHFFFAOYSA-N 0.000 claims 12
- 229950004345 Properidine Drugs 0.000 claims 12
- 229940069956 Propoxyphene Drugs 0.000 claims 12
- 229960004739 Sufentanil Drugs 0.000 claims 12
- VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 claims 12
- WDEFBBTXULIOBB-WBVHZDCISA-N Tilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 claims 12
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N Tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 12
- 229960004380 Tramadol Drugs 0.000 claims 12
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 12
- 206010046494 Urge incontinence Diseases 0.000 claims 12
- UVITTYOJFDLOGI-LICQEQMYSA-N [(2S,5R)-1,2,5-trimethyl-4-phenylpiperidin-4-yl] propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)C[C@H](C)N(C)C[C@H]1C UVITTYOJFDLOGI-LICQEQMYSA-N 0.000 claims 12
- 230000003444 anaesthetic Effects 0.000 claims 12
- 239000003242 anti bacterial agent Substances 0.000 claims 12
- 230000001078 anti-cholinergic Effects 0.000 claims 12
- 230000000843 anti-fungal Effects 0.000 claims 12
- 230000000648 anti-parkinson Effects 0.000 claims 12
- 230000000840 anti-viral Effects 0.000 claims 12
- 239000000939 antiparkinson agent Substances 0.000 claims 12
- 230000003115 biocidal Effects 0.000 claims 12
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 claims 12
- 229960001736 buprenorphine Drugs 0.000 claims 12
- 239000000480 calcium channel blocker Substances 0.000 claims 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 12
- 229960004126 codeine Drugs 0.000 claims 12
- 229950003851 desomorphine Drugs 0.000 claims 12
- 229960004193 dextropropoxyphene Drugs 0.000 claims 12
- 229960003461 dezocine Drugs 0.000 claims 12
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 claims 12
- 229960002069 diamorphine Drugs 0.000 claims 12
- 229960000920 dihydrocodeine Drugs 0.000 claims 12
- 229950011187 dimenoxadol Drugs 0.000 claims 12
- 239000003937 drug carrier Substances 0.000 claims 12
- 229950010920 eptazocine Drugs 0.000 claims 12
- IPOPQVVNCFQFRK-UHFFFAOYSA-N ethyl 1-(3-hydroxy-3-phenylpropyl)-4-phenylpiperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 229960001410 hydromorphone Drugs 0.000 claims 12
- 229950009272 isomethadone Drugs 0.000 claims 12
- 229960003029 ketobemidone Drugs 0.000 claims 12
- 229960000365 meptazinol Drugs 0.000 claims 12
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 claims 12
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 12
- 239000004084 narcotic analgesic agent Substances 0.000 claims 12
- 229960004300 nicomorphine Drugs 0.000 claims 12
- 229960004013 normethadone Drugs 0.000 claims 12
- 229960001027 opium Drugs 0.000 claims 12
- 229960002085 oxycodone Drugs 0.000 claims 12
- 229960005118 oxymorphone Drugs 0.000 claims 12
- 229960005301 pentazocine Drugs 0.000 claims 12
- 229960000482 pethidine Drugs 0.000 claims 12
- 239000003772 serotonin uptake inhibitor Substances 0.000 claims 12
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical group C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 claims 12
- 229960001402 tilidine Drugs 0.000 claims 12
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 12
- 230000003110 anti-inflammatory Effects 0.000 claims 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 11
- 229910052799 carbon Inorganic materials 0.000 claims 10
- LLPOLZWFYMWNKH-CMKMFDCUSA-N Hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 9
- WTJBNMUWRKPFRS-UHFFFAOYSA-N Hydroxypethidine Chemical compound C=1C=CC(O)=CC=1C1(C(=O)OCC)CCN(C)CC1 WTJBNMUWRKPFRS-UHFFFAOYSA-N 0.000 claims 9
- ZBAFFZBKCMWUHM-UHFFFAOYSA-N Propiram Chemical compound C=1C=CC=NC=1N(C(=O)CC)C(C)CN1CCCCC1 ZBAFFZBKCMWUHM-UHFFFAOYSA-N 0.000 claims 9
- 150000004677 hydrates Chemical class 0.000 claims 9
- 229960000240 hydrocodone Drugs 0.000 claims 9
- 229950008496 hydroxypethidine Drugs 0.000 claims 9
- 229950003779 propiram Drugs 0.000 claims 9
- 125000004438 haloalkoxy group Chemical group 0.000 claims 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 7
- 150000007513 acids Chemical class 0.000 claims 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims 6
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims 5
- GPZLDQAEBHTMPG-UHFFFAOYSA-N Clonitazene Chemical compound N=1C2=CC([N+]([O-])=O)=CC=C2N(CCN(CC)CC)C=1CC1=CC=C(Cl)C=C1 GPZLDQAEBHTMPG-UHFFFAOYSA-N 0.000 claims 4
- 229950001604 Clonitazene Drugs 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims 3
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims 3
- 125000005347 halocycloalkyl group Chemical group 0.000 claims 3
- 125000005350 hydroxycycloalkyl group Chemical group 0.000 claims 3
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 125000005842 heteroatoms Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 229940035674 ANESTHETICS Drugs 0.000 claims 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 claims 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
- 230000035943 smell Effects 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 0 *CCCCCC1N=NC(c(cc2)ccc2C2=CC3(CCNCC3)Oc3ccccc23)=NC1 Chemical compound *CCCCCC1N=NC(c(cc2)ccc2C2=CC3(CCNCC3)Oc3ccccc23)=NC1 0.000 description 84
- KSPBEXAAHKCDGM-UHFFFAOYSA-N CCN(C)C(c1ccc(C)cn1)=O Chemical compound CCN(C)C(c1ccc(C)cn1)=O KSPBEXAAHKCDGM-UHFFFAOYSA-N 0.000 description 5
- 102000001490 Opioid Peptides Human genes 0.000 description 5
- 108010093625 Opioid Peptides Proteins 0.000 description 5
- 239000003399 opiate peptide Substances 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- CQUBDZFYWVPEEG-XKZIYDEJSA-N CCN(CC)C(c(nc1)ccc1/C1=C/CCNCCCCc2c1cccc2)=O Chemical compound CCN(CC)C(c(nc1)ccc1/C1=C/CCNCCCCc2c1cccc2)=O CQUBDZFYWVPEEG-XKZIYDEJSA-N 0.000 description 3
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical class O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 3
- 230000002530 ischemic preconditioning Effects 0.000 description 3
- QDYRRFBUVMYCII-UHFFFAOYSA-N CCN(C)C(c1ccc(C)c(O)c1)=O Chemical compound CCN(C)C(c1ccc(C)c(O)c1)=O QDYRRFBUVMYCII-UHFFFAOYSA-N 0.000 description 2
- BNKXWFYUUULVNE-UYOCIXKTSA-N CCN(CC)C(c(cc1)ccc1/C1=C/CCNCCCOc(cc2)c1cc2S(C)(=O)=O)=O Chemical compound CCN(CC)C(c(cc1)ccc1/C1=C/CCNCCCOc(cc2)c1cc2S(C)(=O)=O)=O BNKXWFYUUULVNE-UYOCIXKTSA-N 0.000 description 2
- KMDPIBCWZVMUQL-UHFFFAOYSA-N CCN(CC)C(c(cc1)ccc1C1=CC2(CCNCCC2)Oc(cc2)c1cc2O)=O Chemical compound CCN(CC)C(c(cc1)ccc1C1=CC2(CCNCCC2)Oc(cc2)c1cc2O)=O KMDPIBCWZVMUQL-UHFFFAOYSA-N 0.000 description 2
- PMBNRTXGVLHATL-UHFFFAOYSA-N CCN(CC)C(c(nc1)ccc1C(c1c2)=CC3(CCNCC3)Cc1ccc2O)=O Chemical compound CCN(CC)C(c(nc1)ccc1C(c1c2)=CC3(CCNCC3)Cc1ccc2O)=O PMBNRTXGVLHATL-UHFFFAOYSA-N 0.000 description 2
- ASHLKFBPPTWZLW-UHFFFAOYSA-N CCN(CC)C(c1cc(O)c(C2c(cc(cc3)F)c3OC3(CCNCC3)C2)cc1)=O Chemical compound CCN(CC)C(c1cc(O)c(C2c(cc(cc3)F)c3OC3(CCNCC3)C2)cc1)=O ASHLKFBPPTWZLW-UHFFFAOYSA-N 0.000 description 2
- LBFLVRFHGHYBNC-UHFFFAOYSA-N CCN(CC)C(c1cc(O)c(C2c3ccccc3CC3(CCNCC3)C2)cc1)=O Chemical compound CCN(CC)C(c1cc(O)c(C2c3ccccc3CC3(CCNCC3)C2)cc1)=O LBFLVRFHGHYBNC-UHFFFAOYSA-N 0.000 description 2
- RUYNPLNPNCOCTL-UHFFFAOYSA-N CCN(CC)C(c1cc(O)c(C2c3ccccc3OC3(CCNCC3)C2)cc1)=O Chemical compound CCN(CC)C(c1cc(O)c(C2c3ccccc3OC3(CCNCC3)C2)cc1)=O RUYNPLNPNCOCTL-UHFFFAOYSA-N 0.000 description 2
- MHEXXGICKXSMNP-UHFFFAOYSA-N CCN(CC)C(c1ccc(C2c3cc(O)ccc3CC3(CCNCC3)C2)cn1)=O Chemical compound CCN(CC)C(c1ccc(C2c3cc(O)ccc3CC3(CCNCC3)C2)cn1)=O MHEXXGICKXSMNP-UHFFFAOYSA-N 0.000 description 2
- WNBUCEYKMNELRV-UHFFFAOYSA-N CCN(CC)C(c1ccc(C2c3ccccc3CC3(CCNCC3)C2)cn1)=O Chemical compound CCN(CC)C(c1ccc(C2c3ccccc3CC3(CCNCC3)C2)cn1)=O WNBUCEYKMNELRV-UHFFFAOYSA-N 0.000 description 2
- AQOZBOAKAGTCSS-UHFFFAOYSA-N CS(NCCCCC[n]1nnc(-c(cc2)ccc2C2=CC3(CCNCC3)Oc3ccccc23)n1)(=O)=O Chemical compound CS(NCCCCC[n]1nnc(-c(cc2)ccc2C2=CC3(CCNCC3)Oc3ccccc23)n1)(=O)=O AQOZBOAKAGTCSS-UHFFFAOYSA-N 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 206010021518 Impaired gastric emptying Diseases 0.000 description 2
- 206010054048 Postoperative ileus Diseases 0.000 description 2
- 230000003187 abdominal Effects 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000841 delta opiate receptor agonist Substances 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 229930014694 morphine Natural products 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- ZHUJMSMQIPIPTF-UHFFFAOYSA-N 2-[[2-[[2-[2-[[2-azaniumyl-3-(4-hydroxyphenyl)propanoyl]amino]propanoylamino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NC(C)C(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 ZHUJMSMQIPIPTF-UHFFFAOYSA-N 0.000 description 1
- DDSCNRYOJYAXOK-DUELTEGESA-N 4-[[(2R,5S)-4-[(R)-[4-(diethylcarbamoyl)phenyl]-(3-hydroxyphenyl)methyl]-2,5-dimethylpiperazin-1-yl]methyl]benzoic acid Chemical compound C1=CC(C(=O)N(CC)CC)=CC=C1[C@H](C=1C=C(O)C=CC=1)N1[C@@H](C)CN(CC=2C=CC(=CC=2)C(O)=O)[C@H](C)C1 DDSCNRYOJYAXOK-DUELTEGESA-N 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- KCKAADCFEJSBIS-UHFFFAOYSA-N C/C=S(\C)/NCCCCC[n]1nnc(-c(cc2)ccc2C2=CC3(CCNCC3)Oc3ccccc23)n1 Chemical compound C/C=S(\C)/NCCCCC[n]1nnc(-c(cc2)ccc2C2=CC3(CCNCC3)Oc3ccccc23)n1 KCKAADCFEJSBIS-UHFFFAOYSA-N 0.000 description 1
- UOPPBDMTBQWZNM-UHFFFAOYSA-N CC(C)(C)c1ccc(C(N(C)C)=O)nc1 Chemical compound CC(C)(C)c1ccc(C(N(C)C)=O)nc1 UOPPBDMTBQWZNM-UHFFFAOYSA-N 0.000 description 1
- RCKWGTUATMCVMD-UHFFFAOYSA-N CC(C)c(cc1)cnc1C(N(C)C)=O Chemical compound CC(C)c(cc1)cnc1C(N(C)C)=O RCKWGTUATMCVMD-UHFFFAOYSA-N 0.000 description 1
- RNRAGHXCVORIEU-UHFFFAOYSA-N CC(C)c(ccc(C(NC)=O)c1)c1O Chemical compound CC(C)c(ccc(C(NC)=O)c1)c1O RNRAGHXCVORIEU-UHFFFAOYSA-N 0.000 description 1
- CIOPQQYVQPJQDC-UHFFFAOYSA-N CC(C)c1ccc(C(N(C)C(C)C)=O)nc1 Chemical compound CC(C)c1ccc(C(N(C)C(C)C)=O)nc1 CIOPQQYVQPJQDC-UHFFFAOYSA-N 0.000 description 1
- QVHWPGNORXGZSU-UHFFFAOYSA-O CC(NCCCCCN1N=C(c(cc2)ccc2C2=CC3(CCNCC3)Oc3ccccc23)[NH2+]N1)=O Chemical compound CC(NCCCCCN1N=C(c(cc2)ccc2C2=CC3(CCNCC3)Oc3ccccc23)[NH2+]N1)=O QVHWPGNORXGZSU-UHFFFAOYSA-O 0.000 description 1
- POPFPNQMBBWLIS-UHFFFAOYSA-N CC(NCCCCC[n]1nnc(-c(cc2)ccc2C2=CC3(CCNCC3)OC3C=CC=CC23)n1)=O Chemical compound CC(NCCCCC[n]1nnc(-c(cc2)ccc2C2=CC3(CCNCC3)OC3C=CC=CC23)n1)=O POPFPNQMBBWLIS-UHFFFAOYSA-N 0.000 description 1
- TUWVNSICLKIRGA-UHFFFAOYSA-N CC(NCCCCC[n]1nnc(-c(cc2)ccc2C2=CC3(CCNCC3)Oc3c2cccc3)n1)=O Chemical compound CC(NCCCCC[n]1nnc(-c(cc2)ccc2C2=CC3(CCNCC3)Oc3c2cccc3)n1)=O TUWVNSICLKIRGA-UHFFFAOYSA-N 0.000 description 1
- ODXHLALYJPVMFX-MKKAVFGOSA-N CC/C=C\C(\C(NC)=O)=C/CC Chemical compound CC/C=C\C(\C(NC)=O)=C/CC ODXHLALYJPVMFX-MKKAVFGOSA-N 0.000 description 1
- XXAZQNVVGYYMKK-UHFFFAOYSA-N CC1(C2N=NN(CCCCN)CC2=C)C=CC(C2=CC3(CCNCC3)Oc3ccccc23)=CC1 Chemical compound CC1(C2N=NN(CCCCN)CC2=C)C=CC(C2=CC3(CCNCC3)Oc3ccccc23)=CC1 XXAZQNVVGYYMKK-UHFFFAOYSA-N 0.000 description 1
- JZBNOTYANAOUDW-UHFFFAOYSA-N CCC(C)c(cc1)ccc1C(N(C)C)=O Chemical compound CCC(C)c(cc1)ccc1C(N(C)C)=O JZBNOTYANAOUDW-UHFFFAOYSA-N 0.000 description 1
- NJPTURHUXQBKMA-UHFFFAOYSA-N CCCC(C(CCN)CC(c(ccc(CN(CC)CC)c1)c1N=O)c1c2)Oc1ccc2F Chemical compound CCCC(C(CCN)CC(c(ccc(CN(CC)CC)c1)c1N=O)c1c2)Oc1ccc2F NJPTURHUXQBKMA-UHFFFAOYSA-N 0.000 description 1
- IRPHEFOVXQSPOP-UHFFFAOYSA-N CCCOCC(c1ccc2OCC=C(c(cc3)ccc3C(N(CC)CC)=O)c2c1)=O Chemical compound CCCOCC(c1ccc2OCC=C(c(cc3)ccc3C(N(CC)CC)=O)c2c1)=O IRPHEFOVXQSPOP-UHFFFAOYSA-N 0.000 description 1
- OYZKUOHWLXCJFR-XSONURMYSA-N CCN(C)C(/C(/C=C\C(C)=C)=C/C)=O Chemical compound CCN(C)C(/C(/C=C\C(C)=C)=C/C)=O OYZKUOHWLXCJFR-XSONURMYSA-N 0.000 description 1
- AOHMUEZHBJPIGT-UHFFFAOYSA-N CCN(C)C(c(nc1)ccc1I)=O Chemical compound CCN(C)C(c(nc1)ccc1I)=O AOHMUEZHBJPIGT-UHFFFAOYSA-N 0.000 description 1
- NGYXEWOVOMASSX-UHFFFAOYSA-N CCN(C)C(c1cc(N=O)c(C)cc1)=O Chemical compound CCN(C)C(c1cc(N=O)c(C)cc1)=O NGYXEWOVOMASSX-UHFFFAOYSA-N 0.000 description 1
- XKRIEDJHQAVVIV-LXSLZTFBSA-N CCN(CC)C(C(/C=C\C(\C(c1ccccc1C1)=CC11CCNCCC1)=C/N)=C)=O Chemical compound CCN(CC)C(C(/C=C\C(\C(c1ccccc1C1)=CC11CCNCCC1)=C/N)=C)=O XKRIEDJHQAVVIV-LXSLZTFBSA-N 0.000 description 1
- VZIWSCWIMWVAIR-UHFFFAOYSA-N CCN(CC)C(C(C=C1)=C=CCC=C1C1=CC2(CNCC2)Oc2c1cccc2)=O Chemical compound CCN(CC)C(C(C=C1)=C=CCC=C1C1=CC2(CNCC2)Oc2c1cccc2)=O VZIWSCWIMWVAIR-UHFFFAOYSA-N 0.000 description 1
- NXEQPPHAUCTRKF-UHFFFAOYSA-N CCN(CC)C(C)c(nc1)ccc1C1=CC2(CCNCCC2)Oc2ccc(C)cc12 Chemical compound CCN(CC)C(C)c(nc1)ccc1C1=CC2(CCNCCC2)Oc2ccc(C)cc12 NXEQPPHAUCTRKF-UHFFFAOYSA-N 0.000 description 1
- IIWLNIXFZVVHNP-UHFFFAOYSA-N CCN(CC)C(C1(C)NC=C(C2c3cc(O)ccc3CC3(CCNCC3)C2)C=C1)=O Chemical compound CCN(CC)C(C1(C)NC=C(C2c3cc(O)ccc3CC3(CCNCC3)C2)C=C1)=O IIWLNIXFZVVHNP-UHFFFAOYSA-N 0.000 description 1
- LSJQTFCMCKGRRV-UHFFFAOYSA-N CCN(CC)C(C1C=CC(C(c2c3)=CC4(CCNCCC4)Oc2ccc3S(CC)(=O)=O)=CC1)=O Chemical compound CCN(CC)C(C1C=CC(C(c2c3)=CC4(CCNCCC4)Oc2ccc3S(CC)(=O)=O)=CC1)=O LSJQTFCMCKGRRV-UHFFFAOYSA-N 0.000 description 1
- JIVGLKZIQYWQKU-UHFFFAOYSA-N CCN(CC)C(c(cc1)cc(O)c1C(c1c2)=CC3(CCNCC3)Cc1ccc2F)=O Chemical compound CCN(CC)C(c(cc1)cc(O)c1C(c1c2)=CC3(CCNCC3)Cc1ccc2F)=O JIVGLKZIQYWQKU-UHFFFAOYSA-N 0.000 description 1
- MZAVBABAQLMNSC-UHFFFAOYSA-N CCN(CC)C(c(cc1)cc(O)c1C(c1c2)=CC3(CCNCC3)Oc1ccc2F)=O Chemical compound CCN(CC)C(c(cc1)cc(O)c1C(c1c2)=CC3(CCNCC3)Oc1ccc2F)=O MZAVBABAQLMNSC-UHFFFAOYSA-N 0.000 description 1
- QQPOKIWCIVANSL-UHFFFAOYSA-N CCN(CC)C(c(cc1)cc(O)c1C1=CC2(CCNCCC2)Oc2ccccc12)=O Chemical compound CCN(CC)C(c(cc1)cc(O)c1C1=CC2(CCNCCC2)Oc2ccccc12)=O QQPOKIWCIVANSL-UHFFFAOYSA-N 0.000 description 1
- ROTBWAVZCLGOFG-UHFFFAOYSA-N CCN(CC)C(c(cc1)cc(O)c1C1=CC2(CNCC2)Oc2c1cccc2)=O Chemical compound CCN(CC)C(c(cc1)cc(O)c1C1=CC2(CNCC2)Oc2c1cccc2)=O ROTBWAVZCLGOFG-UHFFFAOYSA-N 0.000 description 1
- JNALGVALUCQACQ-KSEXSDGBSA-N CCN(CC)C(c(cc1)ccc1/C(/c(c(F)ccc1)c1OCC1)=C/CCCCC1=C)=O Chemical compound CCN(CC)C(c(cc1)ccc1/C(/c(c(F)ccc1)c1OCC1)=C/CCCCC1=C)=O JNALGVALUCQACQ-KSEXSDGBSA-N 0.000 description 1
- IRHCKHONRPUCFW-YXSASFKJSA-N CCN(CC)C(c(cc1)ccc1/C(/c1c2)=C/CCNCCCOc1ccc2O)=O Chemical compound CCN(CC)C(c(cc1)ccc1/C(/c1c2)=C/CCNCCCOc1ccc2O)=O IRHCKHONRPUCFW-YXSASFKJSA-N 0.000 description 1
- PSJJJVVLDHRDIB-ZBKNUEDVSA-N CCN(CC)C(c(cc1)ccc1/C1=C/CCNCCCOc2c1c(O)ccc2)=O Chemical compound CCN(CC)C(c(cc1)ccc1/C1=C/CCNCCCOc2c1c(O)ccc2)=O PSJJJVVLDHRDIB-ZBKNUEDVSA-N 0.000 description 1
- GRCREHFUVCOYQZ-GXHLCREISA-N CCN(CC)C(c(cc1)ccc1/C1=C/CCNCCOc2c1c(OC(F)F)ccc2)=O Chemical compound CCN(CC)C(c(cc1)ccc1/C1=C/CCNCCOc2c1c(OC(F)F)ccc2)=O GRCREHFUVCOYQZ-GXHLCREISA-N 0.000 description 1
- PISVSMTUURWWKG-UHFFFAOYSA-N CCN(CC)C(c(cc1)ccc1C(C1(C)C2)=CC3(CCNCCC3)OC1=CC=C2S(C)(=O)=O)=O Chemical compound CCN(CC)C(c(cc1)ccc1C(C1(C)C2)=CC3(CCNCCC3)OC1=CC=C2S(C)(=O)=O)=O PISVSMTUURWWKG-UHFFFAOYSA-N 0.000 description 1
- VVDDZVOEEZNVKE-UHFFFAOYSA-N CCN(CC)C(c(cc1)ccc1C(c1c2)=CC3(CNCC3)Oc1ccc2O)=O Chemical compound CCN(CC)C(c(cc1)ccc1C(c1c2)=CC3(CNCC3)Oc1ccc2O)=O VVDDZVOEEZNVKE-UHFFFAOYSA-N 0.000 description 1
- HIVYEJTUZBMWFO-UHFFFAOYSA-N CCN(CC)C(c(cc1)ccc1C1=CC2(CC(C)NCC2)Oc2ccccc12)=O Chemical compound CCN(CC)C(c(cc1)ccc1C1=CC2(CC(C)NCC2)Oc2ccccc12)=O HIVYEJTUZBMWFO-UHFFFAOYSA-N 0.000 description 1
- WUYXJNVNSNCOPQ-UHFFFAOYSA-N CCN(CC)C(c(cc1)ccc1C1=CC2(CCNCC2)Cc(cc2)c1cc2O)=O Chemical compound CCN(CC)C(c(cc1)ccc1C1=CC2(CCNCC2)Cc(cc2)c1cc2O)=O WUYXJNVNSNCOPQ-UHFFFAOYSA-N 0.000 description 1
- ZYSLYSAQKGEGDQ-UHFFFAOYSA-N CCN(CC)C(c(cc1)ccc1C1=CC2(CCNCC2)Cc2cccc(O)c12)=O Chemical compound CCN(CC)C(c(cc1)ccc1C1=CC2(CCNCC2)Cc2cccc(O)c12)=O ZYSLYSAQKGEGDQ-UHFFFAOYSA-N 0.000 description 1
- JLXQTVALARFFLW-UHFFFAOYSA-N CCN(CC)C(c(cc1)ccc1C1=CC2(CCNCC2)Oc2cccc(N3CCCC3)c12)=O Chemical compound CCN(CC)C(c(cc1)ccc1C1=CC2(CCNCC2)Oc2cccc(N3CCCC3)c12)=O JLXQTVALARFFLW-UHFFFAOYSA-N 0.000 description 1
- QBLPUOOMBNMDOZ-UHFFFAOYSA-N CCN(CC)C(c(cc1)ccc1C1=CC2(CCNCCC2)Oc2cccc(O)c12)=O Chemical compound CCN(CC)C(c(cc1)ccc1C1=CC2(CCNCCC2)Oc2cccc(O)c12)=O QBLPUOOMBNMDOZ-UHFFFAOYSA-N 0.000 description 1
- PZKCLPWZGDGEBF-UHFFFAOYSA-N CCN(CC)C(c(cc1)ccc1C1=CC2(CNCC2)Oc2cccc(O)c12)=O Chemical compound CCN(CC)C(c(cc1)ccc1C1=CC2(CNCC2)Oc2cccc(O)c12)=O PZKCLPWZGDGEBF-UHFFFAOYSA-N 0.000 description 1
- NBFWMDKRULORNP-GUNHTJMXSA-N CCN(CC)C(c(nc1)ccc1/C1=C/CC/N=C\COc2c1c(OC(F)F)ccc2)=O Chemical compound CCN(CC)C(c(nc1)ccc1/C1=C/CC/N=C\COc2c1c(OC(F)F)ccc2)=O NBFWMDKRULORNP-GUNHTJMXSA-N 0.000 description 1
- BJXTYLNQIHMYHK-UHFFFAOYSA-N CCN(CC)C(c(nc1)ccc1C(c1c2)=CC3(CCNCCC3)Oc1ccc2F)=O Chemical compound CCN(CC)C(c(nc1)ccc1C(c1c2)=CC3(CCNCCC3)Oc1ccc2F)=O BJXTYLNQIHMYHK-UHFFFAOYSA-N 0.000 description 1
- VZMRWCDQCYFJGL-UHFFFAOYSA-N CCN(CC)C(c(nc1)ccc1C1=CC2(CCNCC2)Oc2cccc(OC(F)F)c12)=O Chemical compound CCN(CC)C(c(nc1)ccc1C1=CC2(CCNCC2)Oc2cccc(OC(F)F)c12)=O VZMRWCDQCYFJGL-UHFFFAOYSA-N 0.000 description 1
- FRBFXFYMOZCLOJ-UHFFFAOYSA-N CCN(CC)C(c(nc1)ccc1C1=CC2(CCNCCC2)OC2C1=CC(F)=CC2C)=O Chemical compound CCN(CC)C(c(nc1)ccc1C1=CC2(CCNCCC2)OC2C1=CC(F)=CC2C)=O FRBFXFYMOZCLOJ-UHFFFAOYSA-N 0.000 description 1
- GDCHMRACAIKRBC-UHFFFAOYSA-N CCN(CC)C(c(nc1)ccc1C1=CC2(CCNCCC2)Oc2c1cc(C)cc2)=O Chemical compound CCN(CC)C(c(nc1)ccc1C1=CC2(CCNCCC2)Oc2c1cc(C)cc2)=O GDCHMRACAIKRBC-UHFFFAOYSA-N 0.000 description 1
- GUHMAQKAEBUOCY-UHFFFAOYSA-N CCN(CC)C(c(nc1)ccc1C1=CC2(CNCC2)Oc(cc2)c1cc2O)=O Chemical compound CCN(CC)C(c(nc1)ccc1C1=CC2(CNCC2)Oc(cc2)c1cc2O)=O GUHMAQKAEBUOCY-UHFFFAOYSA-N 0.000 description 1
- HUPVDSXHHKLEKN-UHFFFAOYSA-N CCN(CC)C(c1ccc(C(CC2(CCNCC2)OC2CC=C3)C2=C3OC)cn1)=O Chemical compound CCN(CC)C(c1ccc(C(CC2(CCNCC2)OC2CC=C3)C2=C3OC)cn1)=O HUPVDSXHHKLEKN-UHFFFAOYSA-N 0.000 description 1
- ZQRHAVQVARLTEQ-UHFFFAOYSA-N CCN(CC)C(c1ccc(C(CC2(CCNCC2)Oc2ccc3)c2c3OC)cc1)=O Chemical compound CCN(CC)C(c1ccc(C(CC2(CCNCC2)Oc2ccc3)c2c3OC)cc1)=O ZQRHAVQVARLTEQ-UHFFFAOYSA-N 0.000 description 1
- CMOJWHCTKBRKSI-UHFFFAOYSA-N CCN(CC)C(c1ccc(C2=CC3(CCNCC3)Oc3cccc(OC)c23)[s]1)=O Chemical compound CCN(CC)C(c1ccc(C2=CC3(CCNCC3)Oc3cccc(OC)c23)[s]1)=O CMOJWHCTKBRKSI-UHFFFAOYSA-N 0.000 description 1
- KIMAEXWJJNYXKL-UHFFFAOYSA-N CCN(CC)C(c1ccc(C2c(cc(cc3)S(C)(=O)=O)c3NCCCNCCC2)cc1)=O Chemical compound CCN(CC)C(c1ccc(C2c(cc(cc3)S(C)(=O)=O)c3NCCCNCCC2)cc1)=O KIMAEXWJJNYXKL-UHFFFAOYSA-N 0.000 description 1
- HPONIDJWEXQQJT-UHFFFAOYSA-N CCN(CC)C(c1ccc(C2c3cc(O)ccc3CC3(CCNCC3)C2)cc1)=O Chemical compound CCN(CC)C(c1ccc(C2c3cc(O)ccc3CC3(CCNCC3)C2)cc1)=O HPONIDJWEXQQJT-UHFFFAOYSA-N 0.000 description 1
- ITFSWYMUBNGLCY-UHFFFAOYSA-N CCN(CC)Cc1ccc(C(CC2(CCNCC2)Oc2ccc3)c2c3OC)cn1 Chemical compound CCN(CC)Cc1ccc(C(CC2(CCNCC2)Oc2ccc3)c2c3OC)cn1 ITFSWYMUBNGLCY-UHFFFAOYSA-N 0.000 description 1
- DXZSOGQUXFYVLV-UHFFFAOYSA-N CCN(CCCNC)C(c(cc1)ccc1C1=CC2(CCNCC2)Oc2ccccc12)=O Chemical compound CCN(CCCNC)C(c(cc1)ccc1C1=CC2(CCNCC2)Oc2ccccc12)=O DXZSOGQUXFYVLV-UHFFFAOYSA-N 0.000 description 1
- WQLCWHHWRZOJFW-UHFFFAOYSA-N CCN(CCN(C)C)C(c(cc1)ccc1C1=CC2(CCNCC2)Oc2c1cccc2)=O Chemical compound CCN(CCN(C)C)C(c(cc1)ccc1C1=CC2(CCNCC2)Oc2c1cccc2)=O WQLCWHHWRZOJFW-UHFFFAOYSA-N 0.000 description 1
- MAJLLZIJIUXYNA-UHFFFAOYSA-N CCN(CCNC)C(c(cc1)ccc1C1=CC2(CCNCC2)Oc2ccccc12)=O Chemical compound CCN(CCNC)C(c(cc1)ccc1C1=CC2(CCNCC2)Oc2ccccc12)=O MAJLLZIJIUXYNA-UHFFFAOYSA-N 0.000 description 1
- OYGVFIJYXVEFTA-UHFFFAOYSA-N CCN(CCOC)C(c(cc1)ccc1C1=CC2(CCNCC2)Oc2ccccc12)=O Chemical compound CCN(CCOC)C(c(cc1)ccc1C1=CC2(CCNCC2)Oc2ccccc12)=O OYGVFIJYXVEFTA-UHFFFAOYSA-N 0.000 description 1
- HQFSEQHOELVGFI-SOFYXZRVSA-N CCNC(c(nc1)ccc1/C1=C/CCNCCCOc2c1c(O)ccc2)=O Chemical compound CCNC(c(nc1)ccc1/C1=C/CCNCCCOc2c1c(O)ccc2)=O HQFSEQHOELVGFI-SOFYXZRVSA-N 0.000 description 1
- RGMGGXDMTJTYPP-UHFFFAOYSA-N CCc(cc1)ccc1C(N(C)C(C)C)=O Chemical compound CCc(cc1)ccc1C(N(C)C(C)C)=O RGMGGXDMTJTYPP-UHFFFAOYSA-N 0.000 description 1
- HLXJBOURBWLEQR-UHFFFAOYSA-N CN(C)C(c(cc1)cc(O)c1S1(C)CC1)=O Chemical compound CN(C)C(c(cc1)cc(O)c1S1(C)CC1)=O HLXJBOURBWLEQR-UHFFFAOYSA-N 0.000 description 1
- ONAKURCWCNFQTK-UHFFFAOYSA-N CN(C)CCCNC(c1ccc(C2c3ccccc3OC3(CCNCC3)C2)cc1)=O Chemical compound CN(C)CCCNC(c1ccc(C2c3ccccc3OC3(CCNCC3)C2)cc1)=O ONAKURCWCNFQTK-UHFFFAOYSA-N 0.000 description 1
- CPJJVIXIQNCTHK-UHFFFAOYSA-O CS(C(CCCCCCN1N=C(c(cc2)ccc2C2=CC3(CCNCC3)Oc3c2cccc3)[NH2+]N1)=C)(=O)=O Chemical compound CS(C(CCCCCCN1N=C(c(cc2)ccc2C2=CC3(CCNCC3)Oc3c2cccc3)[NH2+]N1)=C)(=O)=O CPJJVIXIQNCTHK-UHFFFAOYSA-O 0.000 description 1
- VSQSVUWMFMHRIS-UHFFFAOYSA-N CSNCCCC[n]1nnc(-c(cc2)ccc2C2=CC3(CCNCC3)Oc3ccccc23)n1 Chemical compound CSNCCCC[n]1nnc(-c(cc2)ccc2C2=CC3(CCNCC3)Oc3ccccc23)n1 VSQSVUWMFMHRIS-UHFFFAOYSA-N 0.000 description 1
- SBZOARJKACTJLN-UHFFFAOYSA-M C[IH]N(C=C)C(c(nc1)ccc1[Cs](C)I)=O Chemical compound C[IH]N(C=C)C(c(nc1)ccc1[Cs](C)I)=O SBZOARJKACTJLN-UHFFFAOYSA-M 0.000 description 1
- ULKWBVNMJZUEBD-UHFFFAOYSA-N Cc(cc1)ccc1C(N(C)C)=O Chemical compound Cc(cc1)ccc1C(N(C)C)=O ULKWBVNMJZUEBD-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
- 241000668709 Dipterocarpus costatus Species 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Enkephalin L Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 208000008384 Ileus Diseases 0.000 description 1
- 210000004165 Myocardium Anatomy 0.000 description 1
- RJTSILCJEPOBNH-UHFFFAOYSA-N NCCCCCC[n]1nnc(-c(cc2)ccc2C2=CC3(CCNCC3)Oc3ccccc23)n1 Chemical compound NCCCCCC[n]1nnc(-c(cc2)ccc2C2=CC3(CCNCC3)Oc3ccccc23)n1 RJTSILCJEPOBNH-UHFFFAOYSA-N 0.000 description 1
- IBUNXJGYYGKNEG-UHFFFAOYSA-N NCCCCC[n]1nnc(-c(cc2)ccc2C2=CC3(CCNCC3)Oc3ccccc23)n1 Chemical compound NCCCCC[n]1nnc(-c(cc2)ccc2C2=CC3(CCNCC3)Oc3ccccc23)n1 IBUNXJGYYGKNEG-UHFFFAOYSA-N 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N Naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 Naloxone Drugs 0.000 description 1
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 1
- 102000001253 Protein Kinases Human genes 0.000 description 1
- 108060006633 Protein Kinases Proteins 0.000 description 1
- 108010003581 Ribulose-Bisphosphate Carboxylase Proteins 0.000 description 1
- KQWVAUSXZDRQPZ-UMTXDNHDSA-N SNC-80 Chemical compound C1=CC(C(=O)N(CC)CC)=CC=C1[C@H](C=1C=C(OC)C=CC=1)N1[C@@H](C)CN(CC=C)[C@H](C)C1 KQWVAUSXZDRQPZ-UMTXDNHDSA-N 0.000 description 1
- 206010046566 Urinary tract disease Diseases 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural Effects 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006266 hibernation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000002107 myocardial Effects 0.000 description 1
- 230000001962 neuropharmacologic activity Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 201000008125 pain agnosia Diseases 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66717705P | 2005-03-31 | 2005-03-31 | |
| US60/667,177 | 2005-03-31 | ||
| US11/393,133 US7598261B2 (en) | 2005-03-31 | 2006-03-30 | Spirocyclic heterocyclic derivatives and methods of their use |
| US11/393,133 | 2006-03-30 | ||
| PCT/US2006/012081 WO2006105442A2 (en) | 2005-03-31 | 2006-03-31 | Spirocyclic heterocyclic derivatives and methods of their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008534613A JP2008534613A (ja) | 2008-08-28 |
| JP2008534613A5 true JP2008534613A5 (US07462627-20081209-C00021.png) | 2009-05-21 |
| JP5118788B2 JP5118788B2 (ja) | 2013-01-16 |
Family
ID=37054196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008504447A Expired - Fee Related JP5118788B2 (ja) | 2005-03-31 | 2006-03-31 | スピロ複素環式誘導体およびその使用方法 |
Country Status (11)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4976134B2 (ja) * | 2003-10-01 | 2012-07-18 | アドラー コーポレーション | スピロ環複素環誘導体及びそれらを使用する方法 |
| US7598261B2 (en) * | 2005-03-31 | 2009-10-06 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
| US7576207B2 (en) * | 2006-04-06 | 2009-08-18 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
| CN101534819A (zh) * | 2006-09-12 | 2009-09-16 | 阿得罗公司 | 含氮的螺环化合物用于增强认知功能的应用 |
| US8258131B2 (en) * | 2007-08-01 | 2012-09-04 | Mitsubishi Tanabe Pharma Corporation | Fused bicyclic compound |
| RU2010151951A (ru) | 2008-05-20 | 2012-06-27 | Ньюроджесэкс, Инк. (Us) | Общие пролекарства гепатопротектора и ацетаминофена |
| US8598164B2 (en) | 2010-05-06 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| SI2670752T1 (sl) | 2011-02-02 | 2016-10-28 | Vertex Pharmaceuticals Incorporated | Pirolopirazin-spirociklični piperidin amidi kot modulatorji ionskih kanalčkov |
| EP2675812B1 (en) * | 2011-02-18 | 2017-08-30 | Vertex Pharmaceuticals Incorporated | Chroman - spirocyclic piperidine amides as modulators of ion channels |
| AU2012229187B2 (en) | 2011-03-14 | 2016-11-10 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
| AU2013302468B2 (en) | 2012-08-16 | 2017-08-24 | Janssen Pharmaceutica Nv | Substituted pyrazoles as N-type calcium channel blockers |
| US9453002B2 (en) | 2013-08-16 | 2016-09-27 | Janssen Pharmaceutica Nv | Substituted imidazoles as N-type calcium channel blockers |
| SG11201600846WA (en) * | 2013-08-16 | 2016-03-30 | Janssen Pharmaceutica Nv | Substituted imidazoles as n-type calcium channel blockers |
| CN107602515A (zh) * | 2017-10-13 | 2018-01-19 | 南开大学 | 一类5a5b6c三环螺环内酯衍生物及其制备方法和用途 |
| WO2023283743A1 (en) * | 2021-07-16 | 2023-01-19 | Aphiotx Inc. | Sulfamoyl benzene derivatives and uses thereof |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5387587A (en) | 1986-12-23 | 1995-02-07 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Chroman derivatives |
| MX170841B (es) | 1988-09-26 | 1993-09-20 | Goodyear Tire & Rubber | Proceso mejorado para la sintesis catalizada de metacrilaminadas y acrilimidas n-substituidas |
| DE3837809A1 (de) | 1988-11-08 | 1990-05-10 | Merck Patent Gmbh | Tetralinderivate |
| EP0376524B1 (en) | 1988-12-13 | 1995-03-29 | Beecham Group Plc | Benzopyran and related compounds |
| IT1230062B (it) * | 1989-04-18 | 1991-09-27 | Enichem Sintesi | Nuovi silani contenenti almeno due gruppi oxazolidinici, loro preparazione ed impiego. |
| EP0401958B1 (en) | 1989-06-05 | 1995-01-11 | Tokuyama Corporation | Photochromic compound, composition and use thereof |
| JPH03173882A (ja) | 1989-09-29 | 1991-07-29 | Tanabe Seiyaku Co Ltd | クロメン又はチオクロメン誘導体、その製法及びその合成中間体 |
| JP2985322B2 (ja) | 1991-03-01 | 1999-11-29 | 東レ株式会社 | イソキノリン誘導体およびその医薬用途 |
| US5354863A (en) | 1992-01-21 | 1994-10-11 | G. D. Searle & Co. | Opioid agonist compounds |
| GB9202238D0 (en) | 1992-02-03 | 1992-03-18 | Wellcome Found | Compounds |
| GB9203596D0 (en) | 1992-02-20 | 1992-04-08 | Smithkline Beecham Plc | Novel process |
| GB9207400D0 (en) | 1992-04-02 | 1992-05-13 | Smithkline Beecham Plc | Novel use |
| CA2100514C (en) | 1992-07-29 | 2005-03-29 | Johannes A. M. Hamersma | 17-spiromethylene steroids |
| ES2064228B1 (es) | 1992-10-19 | 1995-09-01 | Uriach & Cia Sa J | Nuevas tetralonas con actividad farmacologica, composiciones que las contienen y procedimiento para su preparacion. |
| JPH08505880A (ja) | 1993-01-28 | 1996-06-25 | メルク エンド カンパニー インコーポレーテッド | タキキニン受容体拮抗薬としてのスピロ置換アザ環式化合物 |
| US6031115A (en) | 1993-05-14 | 2000-02-29 | Smithkline Beecham Plc | Process for preparing epoxides |
| AU690576B2 (en) | 1993-08-06 | 1998-04-30 | Smithkline Beecham Spa | Hydroisoquinoline derivatives |
| US5403846A (en) | 1993-11-22 | 1995-04-04 | Merck & Co., Inc. | Spirocycles |
| SE9401727D0 (sv) | 1994-05-18 | 1994-05-18 | Astra Ab | New compounds I |
| US5683628A (en) | 1994-10-17 | 1997-11-04 | Seiko Epson Corp. | Photochromic composition and photochromic resin obtainable by using the same |
| US5628935A (en) | 1994-10-28 | 1997-05-13 | Vision-Ease Lens, Inc. | Photochromic spironaphthopyran compounds |
| WO1996022276A1 (fr) | 1995-01-20 | 1996-07-25 | Nippon Shinyaku Co., Ltd. | Derives d'ethylamine et medicaments |
| US5656420A (en) | 1995-02-24 | 1997-08-12 | University Of Kentucky Research Foundation | Method for employing the delta opioid dadle to extend tissue survival time during ischemia |
| IT1307327B1 (it) | 1995-09-12 | 2001-10-30 | Smithkline Beecham Spa | Derivati idroisochinolinici sostituiti |
| SE9504661D0 (sv) * | 1995-12-22 | 1995-12-22 | Astra Pharma Inc | New compounds |
| JPH09301973A (ja) | 1996-05-09 | 1997-11-25 | Kumiai Chem Ind Co Ltd | クロメン誘導体及びこれを有効成分とする除草剤 |
| US5786378A (en) | 1996-09-25 | 1998-07-28 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters |
| US6218424B1 (en) | 1996-09-25 | 2001-04-17 | Gpi Nil Holdings, Inc. | Heterocyclic ketone and thioester compounds and uses |
| DE19805370A1 (de) * | 1997-03-14 | 1998-09-17 | Gruenenthal Gmbh | Substituierte Aminoverbindungen und ihre Verwendung als analgetisch wirksame Substanzen |
| US6103722A (en) | 1997-07-23 | 2000-08-15 | The Medical College Of Wisconsin Research Foundation Inc. | Ischemic preconditioning |
| US6319939B1 (en) | 1997-12-11 | 2001-11-20 | Janssen Pharmaceutica N.V. | Retinoic acid mimetic anlides |
| GB9804734D0 (en) | 1998-03-05 | 1998-04-29 | Pfizer Ltd | Compounds |
| US6436959B1 (en) | 1998-12-23 | 2002-08-20 | Ortho-Mcneil Pharmaceutical, Inc. | 4-[aryl(piperidin-4-yl)]aminobenzamides |
| FR2787789B1 (fr) | 1998-12-29 | 2002-06-14 | Lipha | Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations |
| GB9912413D0 (en) * | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| TWI243173B (en) * | 1999-11-17 | 2005-11-11 | Akzo Nobel Nv | Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives |
| JP2005231995A (ja) | 1999-12-22 | 2005-09-02 | Meiji Seika Kaisha Ltd | オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物 |
| AU4274401A (en) | 2000-03-24 | 2001-10-03 | Meiji Seika Kaisha | Diphenylalkylamine derivatives useful as opioid delta receptor agonists |
| JP4275288B2 (ja) | 2000-03-31 | 2009-06-10 | 新明和工業株式会社 | ダンプ車輌の油圧制御装置 |
| MXPA02010518A (es) * | 2000-04-27 | 2003-03-10 | Basilea Pharmaceutica Ag | Cromenilmetilpirimidindiaminas como agentes antibacterianos. |
| KR20020012346A (ko) | 2000-08-07 | 2002-02-16 | 유현식 | 신디오탁틱 폴리스티렌을 고수율로 제조하고 반응기부착물을 감소시키는 담지촉매 |
| US6887876B2 (en) | 2000-12-14 | 2005-05-03 | Ortho-Mcneil Pharmaceutical, Inc. | Benzamidine derivatives |
| SE0101765D0 (sv) | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | Novel compounds |
| NZ539828A (en) | 2001-05-18 | 2007-01-26 | Astrazeneca Ab | 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders |
| SE0101766D0 (sv) | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | Novel compounds |
| SE0101769D0 (sv) | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | Novel compounds |
| SE0101771D0 (sv) | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | Novel compounds |
| SE0101773D0 (sv) | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | Novel compounds |
| SE0101770D0 (sv) | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | Novel compounds |
| SE0101767D0 (sv) | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | Novel compounds |
| SE0101768D0 (sv) | 2001-05-18 | 2001-05-18 | Astrazeneca Ab | Novel compounds |
| EP1279666A1 (en) | 2001-07-24 | 2003-01-29 | Pfizer Products Inc. | 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| SE0103313D0 (sv) | 2001-10-03 | 2001-10-03 | Astrazeneca Ab | Novel compounds |
| KR100898562B1 (ko) | 2001-10-15 | 2009-05-20 | 얀센 파마슈티카 엔.브이. | 신규 치환된 4-페닐-4-[1ｈ-이미다졸-2-일]-피페리딘유도체 및 선택적인 비펩타이드 델타 아편유사작용제로서의 그의 용도 |
| PL371297A1 (en) | 2001-10-29 | 2005-06-13 | Ardent Pharmaceuticals, Inc. | Method of treating depression with delta receptor agonist compounds |
| US8575169B2 (en) | 2001-10-29 | 2013-11-05 | Versi Group, Llc | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds |
| US7164021B2 (en) | 2002-09-18 | 2007-01-16 | The Curators Of The University Of Missouri | Opiate analogs selective for the δ-opioid receptor |
| ATE387443T1 (de) | 2002-10-15 | 2008-03-15 | Janssen Pharmaceutica Nv | Substituierte aminochinuclidin verbindungen und deren verwendung als delta-opioid rezeptor liganden |
| WO2004035541A1 (en) | 2002-10-15 | 2004-04-29 | Janssen Pharmaceutica, N.V. | Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators |
| SE0203303D0 (sv) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
| SE0203300D0 (sv) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
| SE0203301D0 (sv) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
| SE0203302D0 (sv) | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
| US7314880B2 (en) | 2003-01-02 | 2008-01-01 | Mount Cook Biosciences, Inc. | Cardioprotective delta opioid receptor agonists and methods of using same |
| SE0300105D0 (sv) | 2003-01-16 | 2003-01-16 | Astrazeneca Ab | Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof |
| SE0300104D0 (sv) | 2003-01-16 | 2003-01-16 | Astrazeneca Ab | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| SE0300103D0 (sv) | 2003-01-16 | 2003-01-16 | Astrazeneca Ab | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| WO2004082612A2 (en) | 2003-03-14 | 2004-09-30 | Optime Therapeutics Inc. | Liposomal formulations and methods of use |
| JP4976134B2 (ja) * | 2003-10-01 | 2012-07-18 | アドラー コーポレーション | スピロ環複素環誘導体及びそれらを使用する方法 |
| US7598261B2 (en) * | 2005-03-31 | 2009-10-06 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
-
2006
- 2006-03-30 US US11/393,133 patent/US7598261B2/en not_active Expired - Fee Related
- 2006-03-31 CA CA002603126A patent/CA2603126A1/en not_active Abandoned
- 2006-03-31 WO PCT/US2006/012081 patent/WO2006105442A2/en active Application Filing
- 2006-03-31 MX MX2007011962A patent/MX2007011962A/es active IP Right Grant
- 2006-03-31 EP EP06749077A patent/EP1871761A4/en not_active Withdrawn
- 2006-03-31 KR KR1020077025148A patent/KR20080005245A/ko not_active Application Discontinuation
- 2006-03-31 JP JP2008504447A patent/JP5118788B2/ja not_active Expired - Fee Related
- 2006-03-31 NZ NZ562144A patent/NZ562144A/en not_active IP Right Cessation
- 2006-03-31 BR BRPI0612189-6A patent/BRPI0612189A2/pt not_active IP Right Cessation
- 2006-03-31 AU AU2006230517A patent/AU2006230517B2/en not_active Ceased
-
2007
- 2007-10-07 IL IL186342A patent/IL186342A0/en unknown
-
2009
- 2009-08-17 US US12/542,302 patent/US8022060B2/en not_active Expired - Fee Related
-
2011
- 2011-04-29 US US13/097,940 patent/US20110218186A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008534613A5 (US07462627-20081209-C00021.png) | ||
| US20200345718A1 (en) | Morphinan Derivatives for the Treatment of Drug Overdose | |
| US20080176885A1 (en) | Novel synergistic opioid-cannabinoid codrug for pain management | |
| EP1868600A1 (de) | Spirocyclishe cyclohexanderivate zur behandlung von substanzabhängigkeit | |
| JP2009526793A5 (US07462627-20081209-C00021.png) | ||
| JP2003528819A5 (US07462627-20081209-C00021.png) | ||
| JP5751831B2 (ja) | 鎮痛耐性抑制剤 | |
| RU2007149044A (ru) | Твердые лекарственные формы наркотических лекарственных средств с улучшенным всасыванием при трансбуккальном введении | |
| JP6279547B2 (ja) | オピオイド誘発性有害薬力学的応答を治療するためのシステムおよび方法 | |
| JP2009533353A5 (US07462627-20081209-C00021.png) | ||
| EP2529739A1 (en) | Therapeutic or prophylactic agent for biliary diseases | |
| JP2006527775A5 (US07462627-20081209-C00021.png) | ||
| WO2007006732A1 (en) | Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist) | |
| WO2020055725A4 (en) | Dopamine d3 receptor selective antagonists/partial agonists and uses thereof | |
| US20030166670A1 (en) | Use of an opioid compound to treat a neurologic or neurogenic disorder | |
| CN1378531A (zh) | 用作nmda受体拮抗剂的取代的吡咯烷－2,3,4－三酮－3－肟衍生物 | |
| US20200352917A1 (en) | Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders | |
| JP2003518119A (ja) | ４−［アリール（８−アザビシクロ［３．２．１］オクタン−３−イル）］アミノ安息香酸誘導体 | |
| JP2010532315A5 (US07462627-20081209-C00021.png) | ||
| US20170217976A1 (en) | 6-(amino acid)-morphinan derivatives in combination with permeation enhancers for use as an orally, rectally, transdermally or nasally administered medicament | |
| Le Bourdonnec et al. | Novel trans-3, 4-dimethyl-4-(3-hydroxyphenyl) piperidines as μ opioid receptor antagonists with improved opioid receptor selectivity profiles | |
| AU2004233582B2 (en) | Pharmaceutical compositon comprising a cathepsin S inhibitor and an opioid | |
| WO2004078178A1 (en) | Buprenorphine compounds for treatment of alcohol dependence and excessive alcohol use | |
| EP1797883A2 (en) | Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid | |
| JP2011513278A5 (US07462627-20081209-C00021.png) |
